Jon Oliner

2.7k total citations · 3 hit papers
8 papers, 2.3k citations indexed

About

Jon Oliner is a scholar working on Molecular Biology, Oncology and Surgery. According to data from OpenAlex, Jon Oliner has authored 8 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 3 papers in Oncology and 2 papers in Surgery. Recurrent topics in Jon Oliner's work include Cholesterol and Lipid Metabolism (2 papers), Cancer Research and Treatments (2 papers) and Angiogenesis and VEGF in Cancer (2 papers). Jon Oliner is often cited by papers focused on Cholesterol and Lipid Metabolism (2 papers), Cancer Research and Treatments (2 papers) and Angiogenesis and VEGF in Cancer (2 papers). Jon Oliner collaborates with scholars based in United States. Jon Oliner's co-authors include Bert Vogelstein, Takashi Tokino, David E. Hill, S E Kern, Kathleen R. Cho, Kenneth W. Kinzler, Janice Nigro, J. Michael Ruppert, Eric R. Fearon and Eugene Healy and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Genes & Development.

In The Last Decade

Jon Oliner

8 papers receiving 2.3k citations

Hit Papers

Scrambled exons 1991 2026 2002 2014 1991 1995 1993 250 500 750

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jon Oliner United States 7 1.8k 995 882 231 222 8 2.3k
Irmgard Schwarte‐Waldhoff Germany 25 1.4k 0.8× 1.2k 1.2× 729 0.8× 168 0.7× 82 0.4× 36 2.1k
Joseph Abecassis France 28 1.6k 0.9× 1.2k 1.2× 1.1k 1.2× 241 1.0× 97 0.4× 57 2.9k
Steven J. Kuerbitz United States 10 1.8k 1.0× 1.6k 1.6× 473 0.5× 172 0.7× 438 2.0× 19 2.6k
Torbjörn Norberg Sweden 11 968 0.5× 825 0.8× 488 0.6× 115 0.5× 107 0.5× 17 1.6k
Fumihiro Higashino Japan 25 1.4k 0.8× 727 0.7× 638 0.7× 536 2.3× 72 0.3× 59 2.2k
Richard K. Rosenberg United States 9 792 0.4× 853 0.9× 340 0.4× 260 1.1× 193 0.9× 11 1.4k
Adam D. Steg United States 20 1.2k 0.7× 852 0.9× 431 0.5× 131 0.6× 55 0.2× 44 1.8k
Kou-Juey Wu Taiwan 22 2.2k 1.2× 1.1k 1.1× 1.2k 1.3× 389 1.7× 61 0.3× 25 3.0k
Yasushi Kasai Japan 27 1.1k 0.6× 721 0.7× 368 0.4× 427 1.8× 146 0.7× 64 2.1k
Kerstin Borgmann Germany 32 1.8k 1.0× 1.2k 1.2× 712 0.8× 497 2.2× 61 0.3× 85 2.7k

Countries citing papers authored by Jon Oliner

Since Specialization
Citations

This map shows the geographic impact of Jon Oliner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jon Oliner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jon Oliner more than expected).

Fields of papers citing papers by Jon Oliner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jon Oliner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jon Oliner. The network helps show where Jon Oliner may publish in the future.

Co-authorship network of co-authors of Jon Oliner

This figure shows the co-authorship network connecting the top 25 collaborators of Jon Oliner. A scholar is included among the top collaborators of Jon Oliner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jon Oliner. Jon Oliner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Wang, Xiaoen, Andrea J. Bullock, Liang Zhang, et al.. (2014). The Role of Angiopoietins as Potential Therapeutic Targets in Renal Cell Carcinoma. Translational Oncology. 7(2). 188–195. 34 indexed citations
2.
Bready, James, Kyung Lee, Kevin C. Graham, et al.. (2014). Abstract 1022: Development and preclinical testing of AMG 780, a fully human antibody targeting angiopoietin 1 (Ang1) and angiopoietin 2 (Ang2). Cancer Research. 74(19_Supplement). 1022–1022. 3 indexed citations
3.
Näär, Anders M., Karen M. Robinson, Jon Oliner, et al.. (1998). Chromatin, TAFs, and a novel multiprotein coactivator are required for synergistic activation by Sp1 and SREBP-1a in vitro. Genes & Development. 12(19). 3020–3031. 173 indexed citations
4.
Oliner, Jon, J. Michael Andresen, Stig K. Hansen, Shi‐Sheng Zhou, & Robert Tjian. (1996). SREBP transcriptional activity is mediated through an interaction with the CREB-binding protein.. Genes & Development. 10(22). 2903–2911. 134 indexed citations
5.
El‐Deiry, Wafik S., Takashi Tokino, Todd Waldman, et al.. (1995). Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues.. PubMed. 55(13). 2910–9. 525 indexed citations breakdown →
6.
Oliner, Jon, et al.. (1994). Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway.. Proceedings of the National Academy of Sciences. 91(7). 2684–2688. 239 indexed citations
7.
Leach, Fredrick S., Takashi Tokino, Paul S. Meltzer, et al.. (1993). p53 Mutation and MDM2 amplification in human soft tissue sarcomas.. PubMed. 53(10 Suppl). 2231–4. 465 indexed citations breakdown →
8.
Nigro, Janice, Kathleen R. Cho, Eric R. Fearon, et al.. (1991). Scrambled exons. Cell. 64(3). 607–613. 774 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026